l-bunolol metabolites in human urine.
Nine radiolabeled compounds were identified in human urine after administering a single oral dose of 3H-l-bunolol (3 mg) to 5 male volunteers. These compounds represented 54.7% of the dose and 71.4% of the isotope excreted in 3 days. Intact bunolol accounted for 14.7% of the dose and its conjugates totaled an additional 5.0%. The major drug metabolite (28.2% of dose) was dihydrobunolol, a reduction product known to have the same pharmacological activity and potency as bunolol. Dihydrobunolol conjugates amounted to 3.9% of the dose. Two minor acidic metabolites were produced by oxidative cleavage of the bunolol side chain, and another minor metabolite (hydroxydihydrobunolol) resulted from both reductive and oxidative biotransformation. Bunolol metabolism in man showed qualitative and quantitative differences from patterns observed in the rat and dog.
D000085:Acetates / Q000652:urine; D000284:Administration, Oral; D000328:Adult; D001711:Biotransformation; D005591:Chemical Fractionation; D002855:Chromatography, Thin Layer; D005965:Glucuronates / Q000652:urine; D006801:Humans; D007773:Lactates / Q000652:urine; D002040:Levobunolol / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000652:urine; D008297:Male; D013431:Sulfates / Q000652:urine
D000085:Acetates; D005965:Glucuronates; D007773:Lactates; D013431:Sulfates; C015810:dihydrobunolol; C015932:hydroxydihydrobunolol; D002040:Levobunolol